SB

Simone Botti

Life Science Investor/CEO (in a quantum superposition)

Tel Aviv District

Invests in

Locations:

  • Min Investment:

    $100,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,500,000.00

Work Experience

2020

  • Senior Partner, Head of Healthcare

    2023

  • Partner

    2022 - 2023

  • Junior Partner

    2020 - 2022

  • Member Board of Directors

    2023

2022

  • Member Board of Directors

    2022

  • Member Board Of Directors

    2022

2022

  • Member Board Of Directors

    2022

  • Member Board Of Directors

    2021

  • Member Board Of Directors

    2021 - 2024

  • President

    2021 - 2023

  • Vice President

    2005 - 2021

    Responsible for furthering cooperation between Italy and Israel especially in matters related to technology transfer and investment in technology, with a focus on biotechnology, medical devices and healthcare IT

2016 - 2020

  • CEO

    2016 - 2020

    Metabomed is a drug discovery company in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. Metabomed focuses on targets which are synthetically lethal for biomarker- defined tumors.

2011 - 2016

  • Head Israel Bioincubator Fund

    2011 - 2016

    Responsible or the management of the Israel Bioincubator, a strategic initiative designed to stimulate innovation by bridging the gap between academic research and the biotechnology industry in Israel. Acting-CEO for Neviah Genomics, an Israel Bioincubator portfolio company developing biomarkers for drug toxicity Acting CEO for Metabomed, an Israel Bioncubator portfolio company in the space of cancer metabolism Board Director of ChanBio